Projects per year
Personal profile
Education
- 2006 Ph.D. (Phrmaceutical Science), National Taiwan University
- 1993 M.S.,(Pharmacy) , National Taiwan University
- 1991 B.S., School of Pharmacy, Taipei Medical University
Experience
- 2016-2019 Director, Department of Pharmaceutical Sciences, Taipei Medical University
- 2012- Associate Professor, Department of Pharmaceutical Sciences, Taipei Medical University
- 2012-2012 Assistant Professor, Department of Pharmaceutical Sciences, Taipei Medical University
- 2007-2012 Assistant Professor, School of Pharmacy, Taipei Medical University
- 2007-2012 Assistant Professor, Graduate Institute of Medical Sciences, Taipei Medical University
- 2004-2007 Assistant Professor, Department of Biochemistry, Taipei Medical University
- 1998-2004 Lecturer, Department of Biochemistry and Molecular Cell Biology, Taipei Medical University
- 1995-1998 Executive Officer, Department of Biochemistry and Molecular Cell Biology, Taipei Medical University
Research Interests
- Discovery and Development of small molecules
- Structure optimization through rational drug design
- Isolation and modification of natural products
Fingerprint
Dive into the research topics where Mei-Hsiang Lin is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
新興影響精神活性物質流行趨勢分析、標準品合成及圖譜建立
1/1/21 → 12/31/21
Project: A - Government Institution › c - Ministry of Health and Welfare
-
109年度「藥品品質分析檢驗方法現代化」委託辦理計畫
5/20/20 → 12/20/20
Project: A - Government Institution › c - Ministry of Health and Welfare
-
108年度「藥品品質分析檢驗方法現代化」委託辦理計畫
4/1/19 → 12/1/19
Project: A - Government Institution › c - Ministry of Health and Welfare
-
107年度「加速暨完備藥品品質檢驗方法國際化」委託辦理計畫分項一：加速藥品品質檢驗方法之國際化
5/28/18 → 12/31/18
Project: A - Government Institution › c - Ministry of Health and Welfare
-
設計及合成香豆素衍生物作為單羧酸轉運蛋白 MCTs抑制劑之活性研究
7/1/17 → 2/28/18
Project: A - Government Institution › b - Ministry of Science and Technology
-
Corrigendum to “Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response” [Eur J Med Chem. 192 2020 112158] (European Journal of Medicinal Chemistry (2020) 192, (S0223523420301252), (10.1016/j.ejmech.2020.112158))
Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., Jun 15 2020, In: European Journal of Medicinal Chemistry. 196, 112329.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Corrigendum to“Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo”[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086] (European Journal of Medicinal Chemistry (2020) 190, (S0223523420300532), (10.1016/j.ejmech.2020.112086))
Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., Sep 1 2020, In: European Journal of Medicinal Chemistry. 201, 112404.Research output: Contribution to journal › Comment/debate › peer-review
-
Corrigendum to “N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression”[Eur. J. Med. Chem. 2020 Jan 1;185:111725] (European Journal of Medicinal Chemistry (2020) 185, (S0223523419308773), (10.1016/j.ejmech.2019.111725))
Mehndiratta, S., Lin, M. H., Wu, Y. W., Chen, C. H., Wu, T. Y., Chuang, K. H., Chao, M. W., Chen, Y. Y., Pan, S. L., Chen, M. C. & Liou, J. P., Aug 1 2020, In: European Journal of Medicinal Chemistry. 199, 112406.Research output: Contribution to journal › Comment/debate › peer-review
Open Access1 Citation (Scopus) -
Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response
Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., Apr 15 2020, In: European Journal of Medicinal Chemistry. 192, p. 112158 112158.Research output: Contribution to journal › Article › peer-review
3 Citations (Scopus) -
Design and synthesis of 3-benzylaminocoumarin-7-O-sulfamate derivatives as steroid sulfatase inhibitors
Hng, Y., Lin, M. H., Lin, T. S., Liu, I. C., Lin, I. C., Lu, Y. L., Chang, C. N., Chiu, P. F., Tsai, K. C., Chen, M. J. & Liang, P. H., Mar 2020, In: Bioorganic Chemistry. 96, 103618.Research output: Contribution to journal › Article › peer-review
5 Citations (Scopus)
Datasets
-
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H. (Contributor), Lin, Y. (Contributor), Chao, M. (Contributor), Sung, T. (Contributor), Wu, Y. (Contributor), Chen, Y. (Contributor), Lin, M. (Contributor), Liou, J. (Contributor), Pan, S. (Contributor) & Yang, C. (Contributor), Unknown Publisher, Dec 29 2018
DOI: 10.6084/m9.figshare.c.4350887.v1, https://springernature.figshare.com/collections/The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/4350887/1
Dataset
-
Additional file 1: of The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H. (Contributor), Lin, Y. (Contributor), Chao, M. (Contributor), Sung, T. (Contributor), Wu, Y. (Contributor), Chen, Y. (Contributor), Lin, M. (Contributor), Liou, J. (Contributor), Pan, S. (Contributor) & Yang, C. (Contributor), Unknown Publisher, Dec 29 2018
DOI: 10.6084/m9.figshare.7531874.v1, https://springernature.figshare.com/articles/Additional_file_1_of_The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/7531874/1
Dataset